Your browser doesn't support javascript.
The effectiveness of the combined use of remdesivir and regdanvimab (CT-P59) in patients with severe COVID-19: A single center retrospective study
Respirology ; 26(SUPPL 3):23-24, 2021.
Article in English | EMBASE | ID: covidwho-1583451
ABSTRACT

Background:

Although the use of remdesivir and systemic corticosteroids have reduced deaths from COVID-19, COVID-19 still has a high mortality rate.

Aims:

To know the effectiveness of the combined use of remdesivir and regdanvimab (CT-P59) in patients with severe COVID-19.

Methods:

From March to early May 2021, 124 severe COVID-19 patients were admitted to Ulsan University Hospital (Ulsan, Korea), and received oxygen therapy and remdesivir. Among them, 25 were administered regdanvimab before oxygen/remdesivir. We retrospectively compared the outcomes of the two groups remdesivir alone group (n = 99 [79.8%]) vs. regdanvimab/remdesivir group (n = 25 [20.2%]).

Results:

The oxygen-free days at day 28 (primary outcome), defined as the number of days a patient was alive and oxygen-free for 28 days from oxygen/remdesivir start, were significantly higher in regdanvimab/remdesivir group (mean ± SD [standard deviation] 19.36 ± 7.87 vs. 22.72 ± 3.66, P = 0.003). The association between the regdanvimab/ remdesivir group and the oxygen-free days was also significant in multivariate analysis (logistic regression), where the initial SpO2/FiO2 ratio (severity index) was adjusted. Further, in the regdanvimab/remdesivir group, the lowest SpO2/FiO2 ratio during treatment was significantly higher (mean ± SD 237.05 ± 89.68 vs. 295.63 ± 72.74, P = 0.003), and the Kaplan-Meier Estimate of oxygen supplement days in surviving patients (at day 28) were significantly shorter (mean ± SD 8.24 ± 7.43 vs. 5.28 ± 3.66, P (log-rank test) = 0.024).

Conclusions:

In severe COVID-19 patients, clinical outcomes could be improved by using regdanvimab in addition to remdesivir.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies / Observational study Language: English Journal: Respirology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies / Observational study Language: English Journal: Respirology Year: 2021 Document Type: Article